ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Accretion Pharmaceuticals Limited approved an alteration to its Memorandum of Association to expand its business objects. The Board also approved increased borrowing and investment limits subject to shareholder approval.
Accretion Pharmaceuticals Limited has provided the web link for shareholders to access its Annual Report for FY 2025-26 and the 3rd AGM notice.
Accretion Pharmaceuticals Limited submitted its annual Structured Digital Database (SDD) compliance certificate for the financial year ended March 31, 2026. The certificate, issued by M/s. Sakhiya & Co., confirms that the company maintains a non-tamperable digital database for tracking UPSI events in accordance with SEBI Insider Trading Regulations.
Accretion Pharmaceuticals Limited informed the National Stock Exchange that it does not fall under the 'Large Corporate' category for the financial year 2026–2027. Consequently, the specific disclosure and compliance requirements for debt security issuance by large entities under SEBI circulars are not applicable to the company.